News

In part one, Alan Wein is joined by Melissa Kaufman, who chaired the AUA Guideline Committee on Genitourinary Syndrome of Menopause (GSM), to discuss these guidelines. Dr. Kaufman emphasizes the ...
Zachary Klaassen hosts Andrew Hahn to discuss future directions in metastatic castration-resistant prostate cancer. Dr. Hahn highlights the "golden era" for targeting cell surface proteins through ...
EVOLUTION study, lutetium PSMA-617, prostate cancer immunotherapy, checkpoint inhibitors, metastatic castration-resistant prostate cancer, EVOLUTION Trial: Ipilimumab/Nivolumab Plus Lutetium-PSMA ...
Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer with poor prognosis and limited treatment options. As NEPC aberrantly expresses delta-like ligand 3 (DLL3), the activity ...
DARPin radioligand therapy, lead-212 radiopharmaceuticals, DLL3 targeted therapy, alpha particle therapy, DARPin-Based Radioligand Therapy Targets DLL3 with Lead-212 for Cancer Treatment with Philippe ...
HIF-2 inhibitor kidney cancer, Casdatifan cabozantinib combination, refractory renal cell carcinoma treatment, AB-521 clinical trial, clear cell RCC therapy, Combination HIF-2α/VEGF Dual Inhibition in ...
CHAI biomarker, using AI to predict BCG vs Gem/Doce response in bladder cancer, achieving 90% success rate, insights on precision medicine, Computational Histology AI Guides Treatment Selection for ...
In [18F]F-PSMA-1007 PET imaging, focal bone uptake without morphological correlate (MC) on CT, is often classified as benign. In [68Ga]Ga-PSMA-11, intense focal uptake without MC in a classical ...
Trimodality therapy (TMT), consisting of maximal transurethral resection of bladder tumor (TURBT) followed by concurrent chemoradiotherapy, has emerged as a bladder-sparing alternative to radical ...
Previous research on Radium-223 treatment patterns in metastatic prostate cancer has been limited to select sites, oncology practices, or claims databases. Limited data exists on the use and outcomes ...
June 4, 2025 At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone ...
PDIGREE phase III adaptive, enrolled 1000+ metastatic kidney cancer patients across 500+ sites, ASCO 2025 results and innovative treatment strategies, PDIGREE Trial Tests Adaptive Immunotherapy ...